FDA Expands EUA for SBECD-enabled Remdesivir
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With
Tag: remdesivir
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
The paper published in Journal of the American Society of Nephrology (JASN) is an expert opinion on the risks of
Solubilization of remdesivir by SBECD using ultrasonication
Hielscher Ultrasonics shows on its website how remdesivir solution can be easily prepared by complexation with sulfobutyl ether beta-cyclodextrin using
A 68-Year-Old Man with Covid-19 and Acute Kidney Injury – Case Records of the Massachusetts General Hospital
The case report discusses the difficulties in the treatment of this patient with acute kidney disease. Acute kidney injury —
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
Pfizer agrees to manufacture Gilead’s coronavirus drug remdesivir
Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday. The multiyear agreement will support efforts to
European Commission secures EU access to Remdesivir for treatment of COVID-19
The European Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand
Australia’s TGA approves remdesivir while Gilead reports reduced mortality risk
The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to
Veklury (remdesivir) becomes the first approved drug for the treatment of COVID-19 in the European Union
On the 3rd of July we arrived to another milestone in the fight against the novel coronavirus infection. Eurpean Comission
Gilead prices remdesivir at 390$/vial for governments
Daniel O’Day, Chairman & CEO, Gilead Sciences posted an open letter yesterday, to share pricing indications for Gilead anti-COVID19 treatment,